MedTrace Logo

Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

NCT00466713 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-05-13

No results posted yet for this study

Summary

This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin-sensitizing medication will improve the heart's ability to metabolize glucose (sugar).

Conditions

  • Dilated Cardiomyopathy

Interventions

DRUG

Rosiglitazone therapy

Sponsors & Collaborators

Principal Investigators

  • Michael Fowler, MB · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00466713 on ClinicalTrials.gov